Samyang Biopharm
Samyang Biopharm (South Korea) has DMF or CEP filings on record for 1 active ingredient. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Samyang Biopharm: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/samyang-biopharm
Overview
Samyang Biopharm is a pharmaceutical company headquartered in 성남시 분당구, South Korea.
Active ingredients with DMF or CEP filings
Substances for which Samyang Biopharm holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Samyang Biopharm in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Samyang Biopharm?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.